Three patients (patients four, five and six) were enrolled and treated at the Therapeutic Dose (0.70 mg/cm2), with patient 4 successfully achieving the primary and secondary endpoints at 90 days post treatment; however, the patient was diagnosed with pre-existing and non-Study related metastatic disease and was excluded from further study evaluation. Patients 5 and 6 have been cancer-free for over a year after a single treatment with our compound TLD-1433!
More information is in the Theralase press release.